- Company
- Champix, conclusion of patent disputes imminent
- by Kim, Jin-Gu Dec 17, 2019 06:34am
- A patent dispute over the Champix(Vareniclin) marks the end. The Patent Court has announced that it will issue a judgment on a patent dispute related to the Champix on the 20th , 4 days later. The result of the Champix patent dispute attracted interest in that it could see the future of domestic salt-modifying drugs after the so-called
- Company
- Venture capital investment on bio sector breaks record again
- by Kim, Jin-Gu Dec 16, 2019 10:55pm
- The new investment volume in pharmaceutical and bio industry is expected to mark the highest figure in the history, despite multiple risks occurred in the year. Following last year’s record-breaking volume, this year’s investment volume is to break the last year’s record. Korean Venture Capital Association (KVCA) recently published a Vent
- Company
- Huons, challenges localization of Hyaluronidase
- by Lee, Seok-Jun Dec 16, 2019 10:55pm
- Huons Group will challenge the global hyaluronidase market worth &8361;3 trillion. HuonsLab, a bio research and development company specializing in Huons Group, announced on 16th that it has signed a commissioned research agreement contract with Panzen, a cell line development company, to develop ‘human gene recombinant hyaluronidase’ cel
- Company
- Collapse of Cialis, 6th place in 4 years
- by An, Kyung-Jin Dec 16, 2019 06:21am
- The market position of Cialis, which squeezed the market for erectile dysfunction with Viagra, was greatly reduced. In the aftermath of the generic drug market by domestic pharmaceutical companies, sales shrank to one-third of patent expiration. The share rank has changed from 1st to 6th place four years ago. Generic products such as 'Palp
- Company
- Industry feels growing pressure on metformin risk
- by Chon, Seung-Hyun Dec 16, 2019 06:21am
- The pharmaceutical industry’s concern over metformin impurity contamination is growing. The industry’s eyes are focused on the government’s action following its ongoing metformin usage status review. Some of pharmaceutical companies are promptly equipping themselves with impurity analyzer a self-testing. ◆MFDS initiates metformin
- Company
- Bayer Korea appoints Freda Lin as a new President
- by Eo, Yun-Ho Dec 13, 2019 10:59pm
- Bayer Korea has announced an appointment of Freda Ta-Ling Lin as a new President , starting from Jan. 1, 2020. The Korean branch’s top executive position has been vacant since the former President Ingrid Drechsel transferred to Bayer’s Turkish branch. From October, Bayer Korea’s Pharmaceuticals division has been managed by Lee Jina, a
- Company
- Boryung Holdings appoints Kim Jung Gyun as New CEO
- by Eo, Yun-Ho Dec 13, 2019 10:59pm
- Boryung Holdings recently convened a board meeting and appointed Chief Operating Officer Kim Jung Gyun as the new Chief Executive Officer. Joined Boryung Pharmaceutical in 2014 as a director, the new CEO Kim Jung Gyun served in Strategic Planning team, Production Management team, Human Resources team and was appointed as an executive di
- Company
- MFDS to wait and see self-test results on metformin
- by Chon, Seung-Hyun Dec 13, 2019 06:34am
- The government seems to have decided to encourage pharmaceutical companies to run their own impurity contamination test on metformin drugs. Unlike the ranitidine and nizatidine incidents, the government means to wait and see the companies’ self-investigation results, rather than to take an action by itself. Basically, metformin would be th
- Company
- Lilly releases first non-reimbursed 'Emgality'
- by Eo, Yun-Ho Dec 13, 2019 06:34am
- Eli Lilly's migraine new drug 'Emgality' was released in Korea. Lilly Korea announced on the 12th that it will release non-reimbursed CGRP-targeted migraines prevention drug, Emgality (Galcanezumab). This drug is a humanized monoclonal antibody that binds to the Calcitonin gene-related peptide (CGRP) molecule which plays a key role in ca
- Company
- Metformin? Pharmaceuticals, maximizes fear of impurities
- by Chon, Seung-Hyun Dec 12, 2019 06:31am
- In the pharmaceutical industry, fear of impurities rarely disappears. As the aftershocks of Valsartan, Ranitidine, and Nizatidine persist, the possibility of detecting impurities in the diabetic Metformin has emerged. Metformin is the most widely used drug for primary diabetes treatment. Therefore, if the drug is suspended due to the detection
